Response to Berry et al's "Cutaneous small-vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination"

Natalie H Matthews; Cayla M Pichan; Alexandra C Hristov; David M Markovitz; Allison M Darland

doi:10.1016/j.jdcr.2021.08.041

Response to Berry et al's "Cutaneous small-vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination"

JAAD Case Rep. 2022 Nov:29:62-63. doi: 10.1016/j.jdcr.2021.08.041. Epub 2022 Jan 21.

Authors

Natalie H Matthews¹, Cayla M Pichan², Alexandra C Hristov^{1

3}, David M Markovitz⁴, Allison M Darland¹

Affiliations

¹ Department of Dermatology, University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan.
² University of Michigan Medical School, Ann Arbor, Michigan.
³ Department of Pathology, Division of Infectious Diseases, University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan.
⁴ Department of Internal Medicine, Division of Infectious Diseases, University of Michigan School of Medicine, University of Michigan, Ann Arbor, Michigan.

No abstract available

Keywords: COVID-19; Johnson & Johnson adenovirus vector COVID-19 vaccine; SARS-CoV-2; leukocytoclastic vasculitis; small-vessel vasculitis; vaccine.